Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Stock Information for Humanigen Inc.
Loading
Please wait while we load your information from QuoteMedia.